Biogen (BIIB) Payables (2009 - 2026)

Biogen (BIIB) has reported Payables for 18 consecutive years, with $358.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Payables fell 83.25% year-over-year to $358.5 million; the TTM figure through Mar 2026 stood at $358.5 million (down 83.25% YoY), while the FY2025 annual figure was $432.0 million, down 80.12% from the prior year.
• Payables came in at $358.5 million for Q1 2026 at Biogen, down from $432.0 million in the prior quarter.
• The five-year high for Payables was $7.7 billion in Q2 2022, with the low at $358.5 million in Q1 2026.
• Average Payables over 5 years is $3.1 billion, with a median of $2.1 billion recorded in 2025.
• The largest YoY upside for Payables was 1954.89% in 2022 against a maximum downside of 95.02% in 2022.
• Year by year, Payables stood at $6.8 billion in 2022, then climbed by 8.4% to $7.3 billion in 2023, then slumped by 70.4% to $2.2 billion in 2024, then tumbled by 80.12% to $432.0 million in 2025, then dropped by 17.01% to $358.5 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $358.5 million, $432.0 million, and $6.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.